Pancreatic autoantibodies in Crohn's disease: A family study

Gut

Volumn 40, Issue 4, 1997, Pages 481-484

  Seibold, F ^a,b   Mork H ^a   Tanza, S ^a   Muller A ^a   Holzhuter C ^a   Weber, P ^a   Scheurlen, M ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Crohn's disease; Family study; Pancreatic antibodies

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G;

ADULT; AGED; ARTICLE; CROHN DISEASE; ENTERITIS; FAMILY; FEMALE; GENETIC MARKER; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; PANCREAS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

EID: 0030923950     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.40.4.481     Document Type: Article

References (20)

1. Lewkonia RM, Mc Connell RB. Familial prevalence of inflammatory bowel disease - hereditary or environment? Gut 1976; 17: 235.
2. Mayberry JF, Rhodes J, Neecombe RG. Familial prevalence of inflammatory bowel disease in relatives of patients with Crohn's disease. BMJ 1980; 280: 84.
3. Orholm M, Munkholm P, Langholz E, et al. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991; 324: 84-8.
4. Monsén U, Berell O, Johansson C, Hellers G. Prevalence of inflammatory bowel disease among relatives of patients with Crohn's disease. Scand J Gastroenterol 1991; 26: 302.
5. Weterman IT, Pena AS. Familial incidence of Crohn's disease in the Netherlands and a review of the literature. Gastroenterology 1984; 86: 449.
6. Farmer RG. Study of family history among patients with inflammatory bowel disease. Scand J Gastroenterol 1989; 24 (suppl): 64.
7. Yang H, McElree C, Roth M-P, et al. Familial empiric risk for inflammatory bowel disease. Differences between Jews and Non Jews. Gut 1993; 34: 517 24.
8. Elson CO. Experimental models of IBD: lessons from mice. In: Tytgat GNJ, ed. Inflammatory bowel disease. Dordrecht: Kluwer Academic Publishers, 1995: 395-400.
9. Seibold F, Weber P, Scheurlen M. Autoantibodies in IBD patients and their families. In: Tytgat GNJ, ed. Inflammatory bowel disease, Dordrecht: Kluwer Academic Publishers, 1995: 239-43.
10. Seibold F, Weber P, Klein R, Berg PA, Wiedmann KH. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 1992; 33: 657-62.
11. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A subset of antineutrophil anticytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86: 202-10.
12. Rump AJ, Schoelmerich J, Gross V, et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (pANCA) in active ulcerative colitis but not in Crohn's disease. Immunobiology 1990; 181: 406-13.
13. Shanahan F, Duerr R, Rotter JI, et al. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 1992; 103: 456 61.
14. Seibold F, Slametschka D, Gregor M, Weber P. Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology 1994; 107: 532-6.
15. Berberian LS, Valles Ayoub Y, Gordon LK, Targan SR, Braun J. Expression of a novel autoantibody defined by the VH3-15 gene in inflammatory bowel disease and Campylobacter jejuni enterocolitis. J Immunol 1994; 153: 3756-63.
16. Stöcker W, Otte M, Ulrich S, et al. Autoimmunity to pancreatic juice in Crohn's disease. Scand J Gastroenterol 1987; 22 (suppl): 41-52.
17. Seibold F, Weber P, Jenss H, Wiedmann KH. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn's disease. Gut 1991; 32: 1192-97.
18. Malchow H, Ewe K, Brandes JW. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
19. Truelove SC, Witts LJ. Cortisone in ulcerative colitis: final report of a therapeutic trial. BMJ 1955; ii: 1041-8.
20. Lee CW, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastrocnterology 1995; 108: 428-33.